Studies on the antibacterial effects of statins - in vitro and in vivo

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Bergman, Peter ^a   Linde, Charlotte ^b   Pütsep, Katrin ^b   Pohanka, Anton ^a   Normark, Staffan ^b   Henriques Normark, Birgitta ^a,b   Andersson, Jan ^a   Björkhem Bergman, Linda ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; PENICILLIN G; PRAVASTATIN; SIMVASTATIN; ANTIINFECTIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PENICILLIN DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL VIABILITY; BLOOD CULTURE; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG MONITORING; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORAXELLA CATARRHALIS; NONHUMAN; NORMAL HUMAN; RESPIRATORY SYSTEM; SINGLE DRUG DOSE; STAPHYLOCOCCAL PNEUMONIA; VOLUNTEER; BACTERIAL MEMBRANE; CLINICAL TRIAL; DRUG EFFECT; DRUG POTENTIATION; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIAL VIABILITY; MICROBIOLOGICAL EXAMINATION; STREPTOCOCCUS PNEUMONIAE;

BACTERIA (MICROORGANISMS); MORAXELLA CATARRHALIS; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIAL CAPSULES; DRUG SYNERGISM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MORAXELLA (BRANHAMELLA) CATARRHALIS; PENICILLINS; STREPTOCOCCUS PNEUMONIAE;

EID: 80052301109     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024394     Document Type: Article

References (22)

1. Wilt TJ, Bloomfield HE, MacDonald R, Nelson D, Rutks I, et al. (2004) Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 164: 1427-1436.
2. Jain MK, Ridker PM, (2005) Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4: 977-987.
3. Broady R, Levings MK, (2008) Graft-versus-host disease: suppression by statins. Nat Med 14: 1155-1156.
4. Bjorkhem-Bergman L, Acimovic J, Torndal UB, Parini P, Eriksson LC, (2010) Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of ubiquinone supplementation. Anticancer Res 30: 1105-1112.
5. Karp I, Behlouli H, Lelorier J, Pilote L, (2008) Statins and cancer risk. Am J Med 121: 302-309.
6. Bjorkhem-Bergman L, Bergman P, Andersson J, Lindh JD, (2010) Statin treatment and mortality in bacterial infections--a systematic review and meta-analysis. PLoS One 5: e10702.
7. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, et al. (2009) Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med 169: 1658-1667.
8. Horn MP, Knecht SM, Rushing FL, Birdsong J, Siddall CP, et al. (2008) Simvastatin inhibits Staphylococcus aureus host cell invasion through modulation of isoprenoid intermediates. J Pharmacol Exp Ther 326: 135-143.
9. Chaudhry MZ, Wang JH, Blankson S, Redmond HP, (2008) Statin (cerivastatin) protects mice against sepsis-related death via reduced proinflammatory cytokines and enhanced bacterial clearance. Surg Infect (Larchmt) 9: 183-194.
10. Jerwood S, Cohen J, (2008) Unexpected antimicrobial effect of statins. J Antimicrob Chemother 61: 362-364.
11. Welsh AM, Kruger P, Faoagali J, (2009) Antimicrobial action of atorvastatin and rosuvastatin. Pathology 41: 689-691.
12. Rosch JW, Boyd AR, Hinojosa E, Pestina T, Hu Y, et al. (2010) Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease. J Clin Invest 120: 627-635.
13. Chow OA, von Kockritz-Blickwede M, Bright AT, Hensler ME, Zinkernagel AS, et al. (2010) Statins enhance formation of phagocyte extracellular traps. Cell Host Microbe 8: 445-454.
14. Bjorkhem-Bergman L, Lindh JD, Bergman P, (2011) What is a relevant statin concentration in cell-experiments claiming pleiotropic effects? Br J Clin Pharmacol.
15. Tettelin H, Nelson KE, Paulsen IT, Eisen JA, Read TD, et al. (2001) Complete genome sequence of a virulent isolate of Streptococcus pneumoniae. Science 293: 498-506.
16. Cederlund A, Agerberth B, Bergman P, (2010) Specificity in killing pathogens is mediated by distinct repertoires of human neutrophil peptides. J Innate Immun 2: 508-521.
17. MSD, (2011) Zocord. Summary of Product Characteristics (SPC).
18. Meda, (2008) Tikacillin. Summary of Product Characterstics (SPC).
19. Wilding EI, Brown JR, Bryant AP, Chalker AF, Holmes DJ, et al. (2000) Identification, evolution, and essentiality of the mevalonate pathway for isopentenyl diphosphate biosynthesis in gram-positive cocci. J Bacteriol 182: 4319-4327.
20. Zhang L, Feng L, Zhou L, Gui J, Wan J, et al. (2010) Purification, crystallization and preliminary X-ray analysis of 3-hydroxy-3-methylglutaryl-coenzyme A reductase of Streptococcus pneumoniae. Acta Crystallogr Sect F Struct Biol Cryst Commun 66: 1500-1502.
21. Tomasz A, Waks S, (1975) Mechanism of action of penicillin: triggering of the pneumococcal autolytic enzyme by inhibitors of cell wall synthesis. Proc Natl Acad Sci U S A 72: 4162-4166.
22. Pottz GE, Rampey JH, Benjamin F, (1967) The effect of dimethyl sulfoxide (DMSO) on antibiotic sensitivity of a group of medically important microorganisms: preliminary report. Ann N Y Acad Sci 141: 261-272.